Here are six key points:
1. The financing consists of €15 million, or $16.7 million, in convertible bonds and €5 million, or $5.5 million, in equity. The sole investor in the convertible bonds is Athyrium Capital Management.
2. Additionally, in the equity private placement, Medicrea will issue 1.02 million in common shares.
3. Medicrea will use the funds to further commercialize its UNiD Patient-Specific Rods in the U.S. market.
4. It also plans to begin commercializing the technology in new international markets.
5. Mr. Kienzle, who will also join Medicrea’s board of directors, was a founding member of Globus Medical.
6. He served as Globus Medical’s executive vice president of global sales and marketing.
More articles on devices:
Flower Orthopedics launches the MTP Fusion Plate Portfolio: 3 things to know
NeuroMetrix’s Quell Health Cloud gathered 1M+ hours of Quell therapy, health data: 5 key pointsNeuroMetrix’s Quell Health Cloud gathered 1M+ hours of Quell therapy, health data: 5 key points
Corin Group, FX Solutions sign distribution agreement for US market: 4 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
